Dr Jeffrey Goh, Chair of the ANZGOG Cervical Cancer Tumour Type Working Group, shares updates from the recent meeting on new concepts for trial developments and ITTACc trial status.
Dr Jeffrey Goh is a Senior Staff Medical Oncologist at the Royal Brisbane & Women’s Hospital and a Visiting Medical Oncologist at Greenslopes Private Hospital and ICON Chermside. He is also currently a board member of ANZGOG and Chair of the Cervical Tumour Type Working Group.
“At the last Cervical Cancer Tumour Type Working Group meeting, we proposed to have a “brainstorming” session in early December to stimulate new concepts for trial development in cervical, vulval and vaginal cancers. Dr Goh’s proposed concept of targeted-immunotherapy for recurrent/ metastatic cervical cancer (ITTACc trial concept) has been submitted to BeiGene for funding; the outcome is eagerly awaited. We are also encouraging more translational research within the group.”
To find out more about ANZGOG’s committees, click here.
Since our beginning in 2000, ANZGOG has conducted 37 clinical trial studies, with close to 4000 patients participating in these trials. ANZGOG currently has 13 open trials. To find out more, please visit our trials page.
